Teva Pharmaceutical Industries Limited's Cephalon, Inc. Recalls Treanda Leukemia Drug Due to Glass Fragments

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) US subsidiary Cephalon has recalled a lot of its Treanda leukemia drug, because glass fragments were found in one of the vials. The US Food and Drug Administration (FDA) said in a statement that Cephalon distributed the Treanda lot TB30111 to wholesalers and distributors between March 22 and October 5, 2011, and notified those recipients about the recall on November 18. The FDA instructed hospitals and health care professionals in possession of vials in lot TB30111 to stop using them and quarantine them for return.

Back to news